Close Menu

NEW YORK – Clinical-stage biotech company Five Prime Therapeutics reported data from their Phase I trial of bemarituzumab (FPA144) in patients with FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma (GEA) in the Journal of Clinical Oncology Friday.

In the study, five patients with high FGFR2b-overexpressing GEA had a partial response, yielding an overall response rate of 17.9 percent.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.